Just released: 3 of the best growth stocks to consider buying in January [PREMIUM PICKS]

Premium content from Motley Fool Share Advisor UK

Our monthly Fire Best Buys Now is designed to highlight three of our team’s favorite, most timely items from our growing list of growth-focused fire recommendations, to help Fools build their portfolios.

• Until the end GSKHaleon did about as well as anyone could have hoped.
• The consumer health group has been growing sales at a consistent clip thanks to full control of R&D and marketing budgets, reducing thanks to increased revenue, and M&A to remove low-growth and bulk brands from attractive locations.
• If Haleon can continue to grow sales from ‘Power Brands’ like Sensodyne, Advilagain Theraflu at rates of 5%+ then achieving the medium term goal of consistent growth of 4%-6% is very achievable. Couple that with continued margin improvement and reduced interest payments and you have a recipe for a group that will have plenty of cash to spend on M&A or return to shareholders through its dividend and share buyback programs.
• Those financial considerations and the defensive nature of the consumer health market mean we think Haleon should be considered in January at its current valuation of 20 times forward earnings.